Clinical Trial Update: An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports on the safety and effectiveness of combining Nivolumab and Daratumumab in patients with multiple myeloma across Phase 1 and P…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Multiple Myeloma
• Non-hodgkin Lymphoma

Drugs mentioned

• Daratumumab (Darzalex) (daratumumab)
• nivolumab (Opdivo) (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Non-Hodgkin's Lymphoma, Hodgkin Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-02-17